217 related articles for article (PubMed ID: 16927532)
21. [Viscum album L. (Iscador) in the cat: tolerance, adverse reactions and indications].
Glardon ; Pache ; Magnenat ; Pin ; Parvis
Schweiz Arch Tierheilkd; 2014 Aug; 156(8):381-8. PubMed ID: 25082635
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador.
Elluru S; Duong Van Huyen JP; Delignat S; Prost F; Bayry J; Kazatchkine MD; Kaveri SV
Arzneimittelforschung; 2006 Jun; 56(6A):461-6. PubMed ID: 16927527
[TBL] [Abstract][Full Text] [Related]
23. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo.
Heinzerling L; von Baehr V; Liebenthal C; von Baehr R; Volk HD
J Clin Immunol; 2006 Jul; 26(4):347-59. PubMed ID: 16705487
[TBL] [Abstract][Full Text] [Related]
24. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
25. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series.
Gardin NE
Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
27. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects.
Huber R; Rostock M; Goedl R; Lüdtke R; Urech K; Buck S; Klein R
Eur J Med Res; 2005 Oct; 10(10):411-8. PubMed ID: 16287602
[TBL] [Abstract][Full Text] [Related]
28. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis.
Grossarth-Maticek R; Ziegler R
Eur J Med Res; 2006 Nov; 11(11):485-95. PubMed ID: 17182361
[TBL] [Abstract][Full Text] [Related]
29. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts.
Büssing A; Stumpf C; Tröger W; Schietzel M
Anticancer Res; 2007; 27(4C):2903-10. PubMed ID: 17695469
[TBL] [Abstract][Full Text] [Related]
30. Effects of Iscador preparations on the reactivity of mouse immune system.
Gren A
Neuro Endocrinol Lett; 2009; 30(4):530-4. PubMed ID: 20010495
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10.
Zarković N; Kalisnik T; Loncarić I; Borović S; Mang S; Kissel D; Konitzer M; Jurin M; Grainza S
Cancer Biother Radiopharm; 1998 Apr; 13(2):121-31. PubMed ID: 10850348
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines.
Klingbeil MF; Xavier FC; Sardinha LR; Severino P; Mathor MB; Rodrigues RV; Pinto DS
Oncol Rep; 2013 Nov; 30(5):2316-22. PubMed ID: 24026291
[TBL] [Abstract][Full Text] [Related]
33. Changes in immunological characteristics of white blood cells after administration of standardized mistletoe extract.
Klopp R; Schmidt W; Niemer W; Werner M; Beuth J
In Vivo; 2001; 15(6):447-57. PubMed ID: 11887328
[TBL] [Abstract][Full Text] [Related]
34. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
Stein G; Berg PA
Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
[TBL] [Abstract][Full Text] [Related]
35. Characterization of cytotoxic proteins from mistletoe (Viscum album L.).
Jung ML; Baudino S; Ribéreau-Gayon G; Beck JP
Cancer Lett; 1990 May; 51(2):103-8. PubMed ID: 2344587
[TBL] [Abstract][Full Text] [Related]
36. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
37. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.
Weissenstein U; Kunz M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2016 Aug; 16():271. PubMed ID: 27491866
[TBL] [Abstract][Full Text] [Related]
38. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata).
Eggenschwiler J; von Balthazar L; Stritt B; Pruntsch D; Ramos M; Urech K; Rist L; Simões-Wüst AP; Viviani A
BMC Complement Altern Med; 2007 May; 7():14. PubMed ID: 17493268
[TBL] [Abstract][Full Text] [Related]
39. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials.
Braedel-Ruoff S
Forsch Komplementmed; 2010 Apr; 17(2):63-73. PubMed ID: 20484913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]